Novo Nordisk (NVO)
(Delayed Data from NYSE)
$127.51 USD
-7.37 (-5.46%)
Updated Sep 20, 2024 04:02 PM ET
After-Market: $127.94 +0.43 (0.34%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Price, Consensus and EPS Surprise
NVO 127.51 -7.37(-5.46%)
Will NVO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NVO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NVO
NVO Stock Loses Around $29B in 3 Months: Buy the Dip or Steer Clear?
NVO Gets Positive CHMP Opinion for Wegovy's Label Update in EU
NVO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sanofi Stock Up Almost 23% in 3 Months: Buy, Sell or Hold?
Pfizer Stock Rises 7.3% in 3 Months: Should You Invest Now?
Novo Nordisk (NVO) Gains As Market Dips: What You Should Know
Other News for NVO
Eli Lilly: Sticking With A $1000 Target Ahead Of Q3 Earnings, New Trading Range
UnitedHealth, Cigna, CVS PBMs targeted by FTC over inflated insulin prices
Novo Nordisk down 6% on data for oral weight loss drug monlunabant
Novo Nordisk down 6% on data for oral weight loss drug monlunabant
Novo Nordisk down 6% on data for oral weight loss drug onlunabant